Arrien Pharmaceuticals Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

Arrien Pharmaceuticals General Information

Description

Operator of a drug discovery company intended to develop treatments for neurodegenerative diseases. The company focuses on developing small molecule therapies targeting key biological pathways, including protein kinase signaling, nuclear hormone receptors, and immuno-oncology/checkpoint pathways, enabling researchers to address a range of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

Contact Information

Website
www.arrienpharma.com
Ownership Status
Out of Business
Financing Status
Formerly Angel backed
Corporate Office
  • 9980 South, 300 West
  • Suite 200
  • Salt Lake City, UT 84070
  • United States
+1 (801)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 9980 South, 300 West
  • Suite 200
  • Salt Lake City, UT 84070
  • United States
+1 (801)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Arrien Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 10-Jan-2025 Completed Out of Business
2. Angel (individual) 12-Sep-2011 Completed Pre-Clinical Trials
1. Angel (individual) 01-Jul-2011 Completed Pre-Clinical Trials
To view Arrien Pharmaceuticals’s complete valuation and funding history, request access »

Arrien Pharmaceuticals Patents

  • 44

    Total Documents Applications and Grants

  • Total Patents Families

  • 41

    Granted

  • 3

    Pending

  • Expiring in next 12 mo

Arrien Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3870177-A1 Pyrazolyl compounds and methods of use thereof Pending 26-Oct-2018
US-20200131154-A1 Pyrazolyl compounds and methods of use thereof Active 26-Oct-2018
CA-3121470-A1 Pyrazolyl compounds and methods of use thereof Pending 26-Oct-2018
US-11053221-B2 Substituted pyrimidines for inhibiting embryonic leucine zipper kinase activity Active 26-Oct-2018
ES-2788660-T3 2,3-dihydro-1h-inden-1-one derivatives as orphan receptor antagonists related to gamma retinoic acid (ror gamma) for the treatment of multiple sclerosis Active 10-Sep-2013 A61K31/5375
To view Arrien Pharmaceuticals’s complete patent history, request access »

Ready to get started?

Request a free trial

Arrien Pharmaceuticals FAQs

  • When was Arrien Pharmaceuticals founded?

    Arrien Pharmaceuticals was founded in 2011.

  • Where is Arrien Pharmaceuticals headquartered?

    Arrien Pharmaceuticals is headquartered in Salt Lake City, UT.

  • What industry is Arrien Pharmaceuticals in?

    Arrien Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Arrien Pharmaceuticals a private or public company?

    Arrien Pharmaceuticals is a Private company.

  • What is Arrien Pharmaceuticals’s current revenue?

    The current revenue for Arrien Pharmaceuticals is .

  • How much funding has Arrien Pharmaceuticals raised over time?

    Arrien Pharmaceuticals has raised $2M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »